Part I: General Principles.- Epidemiology and etiology of glioblastoma.- The role of Molecular Genetics of Glioblastoma in the Clinical Setting.- Neurosurgical Approach to the Patient with Glioblastoma.- Machine Learning Approaches Pertinent to Glioma Classification.- Histopathology of Adult and Pediatric Glioblastoma.- Principles of Radiation Therapy for Glioblastoma Patients.- 'Implementing Molecular Pathology in a Developing Country.- Part II: Molecular Pathology of Glioblastoma.- Molecular Stratification of Adult and Pediatric High Grade Gliomas.- Genomic Heterogeneity of Aggressive Pediatric and Adult Diffuse Astrocytomas.- Immunohistochemical Surrogates for Molecular Pathology.- Part III: Key Molecular Pathways in Glioblastoma Development and Progression.- Learning-Based Automated Methods for Brain Tumor Segmentation, Subtype Classification, Tracking and Patient Survival Prediction.- Rodent Brain Tumor Models for Neuro-Oncology Research.- Stem cell based modelling of glioblastoma.- The Neuroscience of Glioblastoma
This volume provides a balanced and realistic review of the current state of glioblastoma, ranging from traditional histological review, molecular pathology of glioma, modern radiomics, neurosurgical focus, and integration of treatment plans by neuro-oncologists. The book reviews basic principles such as epidemiology and etiology, and modern 2016 WHO classification of CNS tumors. Chapters cover a general overview of common molecular techniques used in molecular pathology, molecular pathology in a developing country, key drivers of patient outcomes and predictors of response to radiation and/or chemotherapy treatment, and immunohistochemical surrogates for key molecular pathology. It concludes with reviews on radiomics, animal and stem cell models of glioblastoma, and a chapter on the emerging field of Glioblastoma Neuroscience.
Precision Molecular Pathology of Glioblastoma is intended for pathology residents and fellows interested in glioblastoma, general surgical pathologists who need reviews on how to implement modern glioblastoma classification, as well as neuro-radiologists, oncologists, and radiation oncologists needing a holistic perspective to glioblastoma diagnosis and management.
Jose Javier Otero, M.D., Ph.D. Director of NeuropathologyThe Ohio State University College of MedicineDepartment of Pathology333 West 10th Ave.Columbus, OH 43210
Dr. Otero is the Director of Neuropathology at The Ohio State University College of Medicine. Neuropathology at Ohio State is responsible for all Surgical Neuropathology and Autopsy Diagnostics for James Cancer Center and Wexner Medical Center, in addition to reviewing consults from community pathologists throughout the United States. Dr. Otero obtained his M.D., Ph.D. degree from Northwestern University (Chicago, IL) where he was mentored by Dr. John Kessler during his graduate dissertation. He then transitioned to University of California, San Francisco for anatomic pathology and neuropathology residency, followed by a post-doctoral fellowship in the laboratory of Dr. David Rowitch. Dr. Otero is an expert in developmental neurobiology and surgical neuropathology.
Aline Becker, M.D., Ph.D.The Ohio State University Comprehensive Cancer Center - James Cancer HospitalDepartment of Radiation Oncology400 W 12th AvenueColumbus, OH 43210E-Mail: firstname.lastname@example.org
Dr. Becker is a physician-scientist formally trained as anatomic pathologist in her home country of Brazil, with large experience in Neuropathology and Molecular Pathology of adult and pediatric brain tumors. She obtained her Neuropathology training at the University of Sao Paulo, campus Ribeirao Preto, a world-renowned institution and one of the premier academic centers for Neuro-Oncology in Brazil. Her Doctoral degree in Molecular Pathology was obtained under the mentorship from Dr. Rui Manuel Reis. She is currently the Research Neuropathologist (Senior Research Associate) in the Chakravarti laboratory at The Ohio State University, where she has worked in the discovery and validation of molecular biomarkers, development of new treatments with small molecule inhibitors and FLASH radiation, and elucidation of treatment resistance mechanisms in glioblastoma.